Repare Therapeutics Inc (RPTX)
US Market

Repare Therapeutics (RPTX) Stock Price & Analysis


RPTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$8.07 - $18.68
Previous Close$12.36
Average Volume (3M)186.06K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$370.35M
Total Debt (Recent Filing)$5.89M
Price to Earnings (P/E)-16.8
Next EarningsMar 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.73
Shares Outstanding41,961,510
Standard Deviation0.16
10 Day Avg. Volume126,420
30 Day Avg. Volume186,062
Price to Book (P/B)1.70
Price to Sales (P/S)4.65
Price to Cash Flow (P/CF)57.90
P/FCF Ratio18.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside100.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Repare Therapeutics’s price range in the past 12 months?
Repare Therapeutics lowest stock price was $8.06 and its highest was $18.68 in the past 12 months.
    What is Repare Therapeutics’s market cap?
    Currently, no data Available
    When is Repare Therapeutics’s upcoming earnings report date?
    Repare Therapeutics’s upcoming earnings report date is Mar 01, 2023 which is in 22 days.
      How were Repare Therapeutics’s earnings last quarter?
      Repare Therapeutics released its earnings results on Nov 09, 2022. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of $0.021 by $1.689.
        Is Repare Therapeutics overvalued?
        According to Wall Street analysts Repare Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Repare Therapeutics pay dividends?
          Repare Therapeutics does not currently pay dividends.
          What is Repare Therapeutics’s EPS estimate?
          Repare Therapeutics’s EPS estimate is -$0.7.
            How many shares outstanding does Repare Therapeutics have?
            Repare Therapeutics has 41,961,510 shares outstanding.
              What happened to Repare Therapeutics’s price movement after its last earnings report?
              Repare Therapeutics reported an EPS of $1.71 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went up 9.178%.
                Which hedge fund is a major shareholder of Repare Therapeutics?
                Among the largest hedge funds holding Repare Therapeutics’s share is ARK Investment Management LLC. It holds Repare Therapeutics’s shares valued at 32M.


                  Repare Therapeutics Stock Smart Score

                  The Repare Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Repare Therapeutics Inc

                  Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Aurinia Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis